Hypoglycemic effect of deoxynojirimycin-polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism

Chemico-Biological Interactions

Volumn 225, Issue , 2015, Pages 70-79

  Li, You Gui ^a   Ji, Dong Feng ^a   Zhong, Shi ^a   Lin, Tian Bao ^a   Lv, Zhi Qiang ^a  

^a INSTITUTE OF PLANT PROTECTION AND MICROBIOLOGY   (China)

Author keywords

Deoxynojirimycin; Glucose metabolism; Polysaccharide; Type 2 diabetes

Indexed keywords

1 DEOXYNOJIRIMYCIN; 6 PHOSPHOFRUCTOKINASE; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBOXYLYASE; CREATININE; DEOXYNOJIRIMYCIN POLYSACCHARIDE; FRUCTOSE BISPHOSPHATASE; GLUCOKINASE; GLUCOSE 6 PHOSPHATASE; GLYCOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; LIPID PEROXIDE; LIPOPROTEIN LIPASE; MALONALDEHYDE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); POLYSACCHARIDE; PYRUVATE CARBOXYLASE; PYRUVATE DECARBOXYLASE E1; PYRUVATE KINASE; PYRUVIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 6 PHOSPHOFRUCTOKINASE ISOENZYME L; DEOXYNOJIRIMYCINE; GLUCOSAMINE; GLUCOSE BLOOD LEVEL; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PYRUVATE DECARBOXYLASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIVER METABOLISM; LIVER PROTECTION; MALE; MOUSE; MUSCLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; INSTITUTE FOR CANCER RESEARCH MOUSE; LIVER; METABOLISM; PHYSIOLOGY; RANDOMIZATION; WESTERN BLOTTING;

MUS;

1-DEOXYNOJIRIMYCIN; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FRUCTOSE-BISPHOSPHATASE; GLUCOKINASE; GLUCOSAMINE; GLUCOSE-6-PHOSPHATASE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED ICR; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PHOSPHOFRUCTOKINASE-1, LIVER TYPE; PYRUVATE CARBOXYLASE; PYRUVATE DECARBOXYLASE; RANDOM ALLOCATION;

EID: 84916886163     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.11.003     Document Type: Article

References (45)

1. S.I. Taylor, Deconstructing type 2 diabetes, Cell 97 (1999) 9-12.
2. V. Saini, Molecular mechanisms of insulin resistance in type 2 diabetes mellitus, World J. Diabetes 1 (2010) 68-75.
3. A. Aziz, S. Wheatcroft, Insulin resistance in Type 2 diabetes and obesity: implications for endothelial function, Exp. Rev. Cardiovasc. Ther. 9 (2011) 403-407.
4. L. Pari, N. Rajarajeswari, Efficacy of coumarin on hepatic key enzymes of glucose metabolism in chemical induced type 2 diabetic rats, Chem. Biol. Interact. 181 (2009) 292-296.
5. S. Muthulakshmi, R. Saravanan, Efficacy of azelaic acid on hepatic key enzymes of carbohydrate metabolism in high fat diet induced type 2 diabetic mice, Biochimie 95 (2013) 1239-1244.
6. N.H. Ugochukwu, C.L. Figgers, Modulation of the flux patterns in carbohydrate metabolism in the livers of streptozoticin-induced diabetic rats dietary caloric restriction, Pharmacol. Res. 54 (2006) 172-180.
7. L. Pari, S. Srinivasan, Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats, Biomed. Pharmacother. 64 (2010) 477-481.
8. Y.G. Li, D.F. Ji, S. Zhong, Z.Q. Lv, T.B. Lin, S. Chen, et al., Hybrid of 1-deoxynojirimycin and polysaccharide from mulberry leaves treat diabetes mellitus by activating PDX-1/insulin-1 signaling pathway and regulating the expression of glucokinase, phosphoenolpyruvate carboxykinase and glucose- 6-phosphatase in alloxan-induced diabetic mice, J. Ethnopharmacol. 134 (2011) 961-970.
9. M. Anhauser, Pharmacists seek the solution of a shaman, Drug Discov. Today 8 (2003) 868-869.
10. B. Andallu, V. Suryakantham, B.L. Srikanthi, G.K. Reddy, Effect of mulberry (Morus indica L.) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes, Clin. Chim. Acta 314 (2001) 47-53.
11. J. Naowaboot, P. Pannangpetch, V. Kukongviriyapan, U. Kukongviriyapan, S. Nakmareong, A. Itharat, Mulberry leaf extract restores arterial pressure in streptozotocin-induced chronic diabetic rats, Nut. Res. 29 (2006) 602-608.
12. C. Kuriyama, O. Kamiyama, K. Ikeda, F. Sanae, A. Kato, I. Adachi, et al., In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures, Bioorg. Med. Chem. 16 (2008) 7330-7336.
13. B.G. Winchester, Iminosugars: from botanical curiosities to licensed drugs, Tetrahedron Asymmetry 20 (2009) 645-651.
14. Y.G. Li, D.F. Ji, S. Zhong, T.B. Lin, Z.Q. Lv, G.Y. Hu, et al., 1-deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic mice, Sci. Rep. 3 (2013) 1377.
15. Y.G. Li, D.F. Ji, S. Zhong, Z.Q. Lv, T.B. Lin, Cooperative anti-diabetic effects of deoxynojirimycin-polysaccharide by inhibiting glucose absorption and modulating glucose metabolism in streptozotocin-induced diabetic mice, PLoS ONE 8 (6) (2013) e65892.
16. T. Szkudelski, The mechanism of alloxan and streptozotocin action in β cells of the rat pancreas, Physiol. Res. 50 (2001) 537-546.
17. J.B. Buse, Type 2 diabetes mellitus in, individualizing treatment targets in diabetes care, Nat. Rev. Endocrinol. 7 (2011) (2010) 67-68.
18. K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, P. Ramarao, Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening, Pharmacol. Res. 52 (2005) 313-320.
19. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia 28 (1985) 412-419.
20. P. Palsamy, S. Subramanian, Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats, Chem. Biol. Interact. 179 (2009) 356-362.
21. B.H. Robinson, Lactic academia (disorders of pyruvate carboxylase, pyruvate dehydrogenase), in: C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.), The metabolic and molecular bases of inherited disease, seventh ed., McGraw-Hill, New York, 1995, pp. 1479-1499.
22. K. Berendzen, D.W. Theriaque, J. Shuster, P.W. Stacpoole, Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency, Mitochondrion 6 (2006) 126-135.
23. W. Li, M. Zhang, J. Gu, Z.J. Meng, L.C. Zhao, Y.N. Zheng, et al., Hypoglycemic effect of protopanaxadiol-type ginsenosides and compound K on Type 2 diabetes mice induced by high-fat diet combining with streptozotocin via suppression of hepatic gluconeogenesis, Fitoterapia 83 (2012) 192-198.
24. V.P. Veerapur, K.R. Prabhakar, B.S. Thippeswamy, P. Bansal, K.K. Srinivasan, M.K. Unnikrishnan, et al., Antidiabetic effect of Ficus racemosa Linn stem bark in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats: a mechanistic study, Food Chem. 132 (2012) 186-193.
25. D. LeRoith, β-cell dysfunction and insulin resistance in Type 2 diabetes: role of metabolic and genetic abnormalities, Am. J. Med. 113 (2002) 3S-11S.
26. K. Srinivasan, P. Ramarao, Animal models in type 2 diabetes research: an overview, Indian J. Med. Res. 125 (2007) 451-472.
27. M. Ito, Y. Kondo, A. Nakatani, K. Hayashi, A. Naruse, Characterization of low dose streptozotocin-induced progressive diabetes in mice, Environ. Toxicol. Pharm. 9 (2001) 71-78.
28. M. Roden, E. Bernroider, Hepatic glucose metabolism in humans-its role in health and disease, Best Pract. Res. Clin. Endocrinol. Metab. 17 (2003) 365-383.
29. X.M. Zhang, W.B. Liang, Y.Q. Mao, H. Li, Y. Yang, H. Tan, Hepatic glucokinase activity is the primary defect in alloxan-induced diabetes of mice, Biomed. Pharmacother. 63 (2009) 180-186.
30. V. Vats, S.P. Yadav, J.K. Grover, Effect of T. foenumgraecum on glycogen content of tissues and the key enzymes of carbohydrate metabolism, J. Ethnopharmacol. 85 (2003) 237-242.
31. G.S. Prasath, S.P. Subramanian, Modulatory effects of fisetin, a bioflavonoid, on hyperglycemia by attenuating the key enzymes of carbohydrate metabolism in hepatic and renal tissues in streptozotocin-induced diabetic rats, Eur. J. Pharmacol. 668 (2011) 492-496.
32. L. He, A. Sabet, S. Djedjos, R. Miller, X. Sun, M.A. Hussain, et al., Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein, Cell 137 (2009) 635-646.
33. X. Xia, J. Yan, Y. Shen, K. Tang, J. Yin, Y. Zhang, et al., Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis, PLoS ONE 6 (2011) e16556.
34. M. Foretz, S. Hebrard, J. Leclerc, E. Zarrinpashneh, M. Soty, G. Mithieux, et al., Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state, J. Clin. Invest. 120 (2010) 2355-2369.
35. P. Bansal, P. Paul, J. Mudgal, P.G. Nayak, S.T. Pannakal, K.I. Priyadarsini, et al., Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice, Exp. Toxicol. Pathol. 64 (2012) 651-658.
36. U. Beisiegel, New aspects on the role of plasma lipases in lipoprotein catabolism and atherosclerosis, Atherosclerosis 124 (1996) 1-8.
37. M.R. Taskinen, Lipoprotein lipase in diabetes, Diabetes Metab. Rev. 3 (1987) 551-570.
38. Jochen G. Schneider, Max von Eynatten, Klaus G. Parhofer, Jan E. Volkmer, Stephan Schiekofer, Andreas Hamann, et al., Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo, Atherosclerosis 175 (2004) 325-331.
39. H. Yagyu, S. Ishibashi, Z. Chen, J. Osuga, M. Okazaki, S. Perrey, et al., Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice, J. Lipid Res. 40 (1999) 1677-1685.
40. K. Tsutsumi, Y. Inoue, A. Shima, K. Iwasaki, M. Kawamura, T. Murase, The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis, J. Clin. Invest. 92 (1993) 411-417.
41. L. Bey, P. Maigret, H. Laouenan, M.T. Hamilton, Induction of lipoprotein lipase gene expression in 3t3-l1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug, Pharmacology 66 (2002) 51-56.
42. J.C. Verd, C. Peris, M. Alegret, C. Díaz, G. Hernández, M. Vázquez, et al., Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits, Br. J. Pharmacol. 127 (1999) 1479-1485.
43. Y.F. Niu, W.P. Liu, C.F. Tian, M. Xie, L. Gao, Z. Chen, et al., Effects of bis(afurancarboxylato) oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats, Eur. J. Pharmacol. 572 (2007) 213-219.
44. K.R. Senthil, M. Ponmozhi, P. Viswanathan, et al., Activity of cassia auriculata leaf extract in rats with alcoholic liver injury, J. Nutr. Biochem. 14 (2003) 452-458.
45. H. Lei, Q. Wang, S.Z. Guo, J.C. Han, H.J. Sun, X.X. Zhang, et al., The protective effect of MT-α-glucan against streptozotocin (STZ)-induced NIT-1 pancreatic β-cell damage, Carbohydr. Polym. 92 (2013) 1211-1217.